No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 17.1x · 10Y median 3.8x · 68th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:28:41.887Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Surrozen, Inc. (SRZN) stock was $26.37 as of Oct 6, 2026, 4:00 PM EDT, down 9.47% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +112.0% · 3-year avg +63.3%/yr · 5-year avg -20.8%/yr
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Biotechnology · South San Francisco, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-1.10
Revenue Est.
$475000.00
Last Quarter Results
EPS
$-2.10
vs Estimate
$-1.26
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SRZN | $197.18M | $26.37 | -9.47% | +112.02% | -20.80% | N/A | N/A |
| 2XGN | $197.87M | $8.19 | -3.19% | -22.71% | -8.40% | N/A | vs SRZN |
| 3RNAC | $198.33M | $6.75 | -5.46% | -29.81% | -44.03% | -33.65% | vs SRZN |
| 4ALEC | $200.96M | $1.81 | -9.05% | -39.91% | -39.17% | N/A | vs SRZN |
| 5RXST | $192.49M | $4.65 | -2.31% | -45.75% | -19.19% | N/A | vs SRZN |
| 6ZNTL | $190.07M | $2.67 | -3.96% | +72.22% | -47.34% | N/A | vs SRZN |
forward FY estimate
N/A
$5.00M
vs Estimate
$467250.00
Consensus Rating
Based on 5 analysts
Average Price Target
$48.40
+83.5% upside
Low
$40.00
Current
$26.37
High
$54.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.11 | $-1.10 | $-1.09 | 2 |
| Quarter ending Dec 2026 | $-1.06 | $-0.87 | $-0.67 | 2 |
| Quarter ending Mar 2027 | $-0.80 | $-0.80 | $-0.80 | 1 |
| Quarter ending Jun 2027 | $-0.84 | $-0.84 | $-0.84 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-7.85 | $-7.01 | $-6.41 | 3 |
| FY 2027 | $-4.32 | $-3.61 | $-2.94 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $475000.00 | $475000.00 | $475000.00 | 5 |
| Quarter ending Dec 2026 | $475000.00 | $475000.00 | $475000.00 | 5 |
| Quarter ending Mar 2027 | $950000.00 | $950000.00 | $950000.00 | 4 |
| Quarter ending Jun 2027 | $950000.00 | $950000.00 | $950000.00 | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $10.24M | $10.74M | $11.60M | 4 |
| FY 2027 | $1.43M | $1.50M | $1.62M | 5 |
